A couple of months ago, Intellia’s leader and founder Nessan Bermingham, Ph.D., left the CRISPR company, but we knew not where.
Today, we found out, and there is little surprise on this occasion as Bermingham has returned full circle, back at Atlas Ventures, the firm that also helped launch Intellia, one of a handful of U.S. biotechs hoping to make good on the early promise of CRISPR gene editing. He first started at the VC firm back in 2002.
Nessan will now be involved “with the formation and leadership of ground-breaking new biotechnology companies as part of the Atlas platform,” the firm said in a brief statement.
“I am thrilled to be working with Atlas again as we translate cutting-edge scientific advances into medicines for patients in need and build great companies,” says Bermingham.
Bermingham co-founded Intellia with Atlas back in 2014, leading the company from its seed investment and incubation at Atlas through to its $108 million IPO.
He first joined Atlas in 2002 and worked on multiple Atlas portfolio companies across various stages
“Nessan is a relentless entrepreneur and operator who has proven his ability to build breakthrough biotech companies from the ground up,” said Jean François Formela, partner at Atlas.
“We are excited to welcome him back to Atlas and look forward to creating transformational new companies with him.”
By Ben Adams
Source: Fierce Biotech
The U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) has introduced several new measures to make it easier to run clinical trials in the country, marking the first time in 20 years the regulatory body has made such an overhaul.
Diabetes drugmaker Novo Nordisk is partnering with Dewpoint Therapeutics in a deal aimed at uncovering new treatments for insulin resistance by targeting cellular droplets known as biomolecular condensates. Dewpoint will receive $55 million upfront from Novo, which plans to develop small molecule drugs against targets discovered using Dewpoint’s technology.
Sanofi has secured approval for Dupixent (dupilumab) from the European Commission (EC) to treat severe atopic dermatitis in children aged six months to five years, who are systemic therapy candidates, in the European Union (EU). This approval makes Dupixent the first and only medicine available in the US and Europe for the treatment of such young children.